Evidence map›Paper›PMID 41920251›Full record

ArticleNatural products and bioprospecting2026

Pyridone alkaloids from an Antarctic endolichenic Tolypocladium sp.

Shasha Li, Ting Yu, Jianju Feng, Yue Shang, Tao Zhang, Shuzhen Chen, Liyan Yu, Maoluo Gan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Natural products and bioprospecting, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shasha LiBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Ting YuBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Jianju FengChina Pharmaceutical Culture Collection, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Yue ShangBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Tao ZhangChina Pharmaceutical Culture Collection, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Shuzhen ChenBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Liyan YuChina Pharmaceutical Culture Collection, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Maoluo GanBeijing Key Laboratory of Technology and Application for Anti-Infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. ganml@imb.pumc.edu.cn.ORCID https://orcid.org/0000-0002-3089-8654

Funding

CAMS Innovation Fund for Medical Sciences 2021-I2M-1-055CAMS Innovation Fund for Medical Sciences 2024-I2M-TS-016National Key R&D Program of China 2024YFC2309604National Microbial Resources Center NMRC-2025-3National Natural Science Foundation of China 82273830
6 · The paper itself

Abstract

Three new pyridone alkaloids, tolypyrone A (1), tolypyrosides A (2) and B (3), and a new tetramic acid 2'-epitolypoalbin (4), along with ten known compounds, were obtained from Tolypocladium sp. CPCC 401485 isolated from an unidentified Antarctic lichen specimen. Structural elucidation of new compounds was achieved by analyses of HRESIMS and NMR spectroscopic data combined with X-ray crystallography, advanced Marfey's method, and ECD calculation. Tolypyrone A (1) was the first 4-pyridone alkaloid with an unusual octahydro-1H-isochromeno[3,4-b]pyridin-4-one triheterocyclic ring system. Compounds 1, 4 and 6 exhibited antimicrobial activities with the minimum inhibition concentration of 16-64 μg/mL.

Indexed as

Antarctic microbesAntimicrobial activitiesEndolichenic fungusPyridone alkaloidsTetramic acidTolypocladium sp.

Identifiers

PMID41920251
PMCPMC13043937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.